Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 7/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | LYN | P07948 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | DDX3X | O00571 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL29351601 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29355523 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL15201213 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2929858 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3138052 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1462774 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL529425 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1977949 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL16431247 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3407874-B1 | FAST DISPERSIBLE PHARMACEUTICAL COMPOSITION COMPRISING TYROSINE-KINASE INHIBITOR | KRKA D D NOVO MESTO (SI) | 2024-05-22 | — | — | EP | claimed |
| EP-1750713-B1 | USE OF IMATINIB TO TREAT LIVER DISORDERS AND VIRAL INFECTIONS | BIONICHE LIFE SCIENCES INC (CA) | 2012-10-17 | — | — | EP | claimed |
| CN-109608436-B | Substituted methyl formyl reagents and methods of using same to improve physicochemical and/or pharmacokinetic properties of compounds | 斯法尔制药私人有限公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2019188446-A1 | MARKER FOR DETERMINING SENSITIVITY OF IRINOTECAN-CONTAINING ANTI-CANCER AGENT THERAPY | 学校法人慶應義塾 | 2019-10-03 | — | — | WO | disclosed |
| US-20180258172-A1 | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS | ZYMOGENETICS INC (US) | 2018-09-13 | — | — | US | disclosed |
| CN-105037398-B | A kind of Bcr Abl amphiploid inhibitor and its production and use | 深圳永泽医药股份有限公司 | 2017-10-24 | — | — | CN | disclosed |
| CN-105037399-B | Bcr-Abl amphiploid inhibitor, preparation method and application thereof | 深圳永泽医药股份有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-105001203-B | A kind of Bcr Abl amphiploid inhibitor and its production and use | 成都大学 | 2017-03-01 | — | — | CN | disclosed |
| CN-105659085-A | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same | 中美冠科生物技术（太仓）有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-9345704-B2 | Materials and methods for suppressing and/or treating neurofibroma and related tumors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| CN-105037398-A | Bcr-Abl amphiploid inhibitor, preparation method and application thereof | UNIV CHENGDU | 2015-11-11 | — | — | CN | disclosed |
| US-20140121214-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING NEUROFIBROMA AND RELATED TUMORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) | 2014-05-01 | — | — | US | disclosed |
| CN-102961755-A | Ligand-functioned super-molecular nano-drug delivery system for treating tumor | UNIV CHONGQING | 2013-03-13 | — | — | CN | disclosed |
| CN-102367477-A | Nucleic acid analysis using saturation dyes | UNIV UTAH RES FOUND | 2012-03-07 | — | — | CN | disclosed |
| CN-101198706-B | Nucleic acid melting analysis with saturating dyes | UNIV UTAH RES FOUND | 2011-10-26 | — | — | CN | disclosed |
| US-20110195975-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING NEUROFIBROMA AND RELATED TUMORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-11 | — | — | US | disclosed |
| CN-101198706-A | Nucleic acid melting analysis with saturating dyes | UNIV UTAH RES FOUND (US) | 2008-06-11 | — | — | CN | disclosed |
| CN-101084005-A | Compounds for flaviviridae treatment | NOVARTIS AG (CH) | 2007-12-05 | — | — | CN | disclosed |
| EP-1635819-A1 | STAUROSPORINE DERIVATIVES FOR HYPEREOSINOPHILIC SYNDROME | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108132-A1 | STAUROSPORINE DERIVATIVES FOR HYPEREOSINOPHILIC SYNDROME | NOVARTIS AG (CH) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121214-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING NEUROFIBROMA AND RELATED TUMORS | KIT, TSG101, VHL | ABL1 53/4885BCR 60/4885KIT 1/4885 |
| US-20110195975-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING NEUROFIBROMA AND RELATED TUMORS | KIT, TSG101, VHL | ABL1 53/4885BCR 60/4885KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.